Tumor-specific activity of precision medicines in the NCI-MATCH trial.

ABSTRACT:

Background

NCI-MATCH is a precision medicine basket trial designed to test the effectiveness of treating cancers based on specific genetic changes in patients' tumors, regardless of cancer type. Multiple subprotocols have each tested different targeted therapies matched to specific genetic aberrations. Most subprotocols exhibited low rates of tumor shrinkage as evaluated across all tumor types enrolled. We hypothesized that these results may arise because these precision cancer therapies have tumor type-specific efficacy, as is common among other cancer therapies.

Methods

To test the hypothesis that certain tumor types are more sensitive to specific therapies than other tumor types, we applied permutation testing to tumor volume change and progression-free survival data from

SUBMITTER: Zhou I 

PROVIDER: S-EPMC10081392 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature